ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
PI3K-Like Protein Kinases
3 - 5 Nov 2015
IFOM, Milan, Italy
Genome instability can be exploited for cancer therapy
Prof Steve Jackson - University of Cambridge, Cambridge, UK
What is the impact of TOR on nuclear dynamics?
Dr Susan Gasser - Friedrich Meischer Institute, Basel, Switzerland
What is the DNA-dependent protein kinase, DNA-PK?
Dr Susan Lees-Miller - University of Calgary, Calgary, Canada
DNA damage response is related to cellular homeostasis
Prof Yossi Shiloh - Tel Aviv University, Tel Aviv, Israel
Checkpoint machinery protects against cancer
Prof Jiri Bartek - Danish Cancer Society Research Centre, Copenhagen, Denmark
Connections between DNA-PK, ATM, ATR and mTOR dependent pathways
Prof Marco Foiani - Scientific director, IFOM, Milan
What is the potential of TOR inhibition for cancer therapy?
Dr Mike Hall - University of Basel, Basel, Switzerland
Mathematical modelling can be used in cancer therapy
Dr Arne Lindqvist - Karolinska Institutet
Recombination can drive tumourogenesis
Prof James Haber - Brandeis University, Waltham, USA
The role of the PI3K and TOR pathways in cancer
Dr David Fruman - University of California, Irvine, USA